STLN (Starling Oncology) Inventories, Work In Process: $0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STLN Starling Oncology Inc STLN
56 GF Score
Price $5.17
GF Value $2.29
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Starling Oncology Inventories, Work In Process?

Starling Oncology STLN +5.56% 56 Inventories, Work In Process is $0.0 Mil as of Mar. 2026. GuruFocus rates STLN with a GF Score™ of 56/100 and a GF Value™ of $2.29 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Starling Oncology's work in process for the quarter that ended in Mar. 2026 was $0.0 Mil.

Starling Oncology Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Starling Oncology's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starling Oncology Inventories, Work In Process Chart

Starling Oncology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Starling Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STLN
56GF Score
Starling Oncology Inc STLN
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starling Oncology Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of $0.0 Mil mean?
Starling Oncology (STLN) has a Inventories, Work In Process of $0.0 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Starling Oncology and its competitors.
Is Starling Oncology's Inventories, Work In Process too high?
Starling Oncology's current Inventories, Work In Process is $0.0 Mil. Overall, Starling Oncology has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Inventories, Work In Process compare to SRTA and CCRN?
Starling Oncology's Inventories, Work In Process of $0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Healthcare Providers & Services company?
A good Inventories, Work In Process depends on the Healthcare Providers & Services industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Starling Oncology and its competitors. Starling Oncology's current Inventories, Work In Process is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Based on GuruFocus' analysis, Starling Oncology (STLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.29, compared to a current price of $5.17 — trading 125.8% above its estimated fair value. The current Inventories, Work In Process is $0.0 Mil. Starling Oncology's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Starling Oncology (STLN), the current Inventories, Work In Process is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starling Oncology (STLN) Overvalued in 2026?

Based on GuruFocus' analysis, Starling Oncology stock appears to be overvalued. The current stock price of $5.17 is trading 125.8% above its estimated GF Value™ of $2.29. GuruFocus considers Starling Oncology to be Significantly Overvalued.

Key valuation signals for STLN:

  • Inventories, Work In Process: $0.0 Mil
  • GF Value™: $2.29 vs. price of $5.17 (125.8% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the STLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starling Oncology Business Description

Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
56GF Score

Get the complete analysis for STLN

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.17
Price
$2.29
GF Value